The Trump administration on Monday pushed the Food and Drug Administration (FDA) to approve skin medicine, which can reduce inflammation and acne.
The White House Office of Management and Budget (OMB) is expected to make the announcement shortly after Trump makes his annual State of the Union address on Jan. 28.
It would be the first time the FDA has approved a drug or device for use in the treatment of acne and skin diseases.
The FDA approved a device that combines three different treatments from the pharmaceutical industry last year.
It was a collaboration between AstraZeneca, Johnson & Johnson, Merck &) and Novartis, according to the agency.
The drug was approved for use to treat inflammatory acne and acne vulgaris, the agency said.
The FDA approved another drug, called Lomifensin, to treat inflammation of the skin, a condition known as seborrheic dermatitis.
Both drugs are made by Astra Zeneca.
AstraZeneca’s drug was the first in a series of drugs it developed to treat skin disorders, according the company.
The company plans to make a second drug, which the FDA is considering, in the next few months.
“We believe this is a very promising development and it will help our customers to improve their overall quality of life,” said Michael Gartrell, chief medical officer at Astra, in a statement.
“We will continue to work with the FDA to make sure that we have the most complete and accurate information for our customers.”
The FDA will be taking comments on the proposed drug until Feb. 13.
It will then be up to the Trump administration to decide whether to approve it.
The agency did not provide any details about the drug, or when it would go on the market.
The president, who has advocated a “skin-care revolution,” has previously praised the Astra-Zeneca device.
“This drug will help millions of people with acne, break up sebum, and heal damaged skin,” Trump said in 2015.
“AstraZenac’s products will make people feel more beautiful, more relaxed, and more comfortable with their skin.”